Increased expression of lncRNA FTH1P3 predicts a poor prognosis and promotes aggressive phenotypes of laryngeal squamous cell carcinoma.


Journal

Bioscience reports
ISSN: 1573-4935
Titre abrégé: Biosci Rep
Pays: England
ID NLM: 8102797

Informations de publication

Date de publication:
28 06 2019
Historique:
received: 17 09 2018
revised: 09 05 2019
accepted: 22 05 2019
pubmed: 31 5 2019
medline: 8 8 2020
entrez: 31 5 2019
Statut: epublish

Résumé

Laryngeal squamous cell cancer (LSCC) is a highly aggressive malignancy in the head and neck region. Recent studies have shown that long noncoding RNAs (lncRNAs) are novel transcripts that play an important role in the progression of LSCC. However, the overall pathophysiological regulation of lncRNAs to LSCC is largely unknown. The present study aimed to determine the clinical significances of lncRNA ferritin heavy chain 1 pseudogene 3 (FTH1P3) and to identify its potential roles in LSCC. Quantitative real-time PCR (qRT-PCR) showed that FTH1P3 expression was significantly up-regulated in LSCC tissues than that in non-neoplastic tissues. High FTH1P3 expression was positively correlated with the poor differentiation, high T classification, positive lymph node metastasis, and advanced clinical stage. Overall survival analysis showed that high levels of FTH1P3 predicted a poor prognosis in LSCC patients. Moreover, elevated expression of FTH1P3 was found to increase LSCC cell proliferation, migration and invasion, and to inhibit cell apoptosis, Conversely, knockdown of FTH1P3 suppressed LSCC cell proliferation, migration and invasion, and induced cell apoptosis. In addition, overexpression of FTH1P3 resulted in an increase in cells in S phase and a decrease in cells in G0/G1 phase, whereas inhibition of FTH1P3 did the opposite effects. Taken together, these results suggested that increased expression of FTH1P3 predicts a poor prognosis and promotes aggressive phenotypes of LSCC by regulating cell proliferation, migration, invasion, apoptosis, and cell cycle, indicating FTH1P3 may serve as a promising therapeutic biomarker for the treatment of LSCC.

Identifiants

pubmed: 31142627
pii: BSR20181644
doi: 10.1042/BSR20181644
pmc: PMC6580104
pii:
doi:

Substances chimiques

MicroRNAs 0
RNA, Long Noncoding 0
long non coding RNA FTH1P3, human 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2019 The Author(s).

Références

N Engl J Med. 2003 Nov 27;349(22):2091-8
pubmed: 14645636
Eur J Cancer. 2005 Mar;41(5):683-93
pubmed: 15763643
Cancer Treat Rev. 2006 Nov;32(7):504-15
pubmed: 16920269
Nat Rev Genet. 2009 Mar;10(3):155-9
pubmed: 19188922
Cell. 2009 Feb 20;136(4):629-41
pubmed: 19239885
Mol Cell. 2011 Sep 16;43(6):904-14
pubmed: 21925379
Eur Arch Otorhinolaryngol. 2012 Sep;269(9):2103-9
pubmed: 22186766
Epigenetics. 2014 Jan;9(1):13-20
pubmed: 24149621
Eur Urol. 2014 Jun;65(6):1140-51
pubmed: 24373479
Biochim Biophys Acta. 2014 Nov;1839(11):1097-109
pubmed: 25159663
PLoS One. 2014 Sep 22;9(9):e108237
pubmed: 25243407
Cancer Res. 2015 Apr 1;75(7):1322-31
pubmed: 25600645
Oncotarget. 2016 Mar 8;7(10):11553-66
pubmed: 26872375
Cell Physiol Biochem. 2016;38(6):2194-206
pubmed: 27183839
DNA Cell Biol. 2016 Sep;35(9):459-70
pubmed: 27213978
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
Gene. 2017 Apr 5;607:47-55
pubmed: 28093311
Tumour Biol. 2017 Jun;39(6):1010428317699417
pubmed: 28631575
Mol Cancer. 2017 Oct 23;16(1):165
pubmed: 29061150
PLoS One. 2017 Nov 2;12(11):e0184746
pubmed: 29095823
JAMA Oncol. 2018 Jul 1;4(7):985-989
pubmed: 29192305
Cell Physiol Biochem. 2018;45(2):844-855
pubmed: 29414815
Am J Transl Res. 2018 Feb 15;10(2):573-580
pubmed: 29511452
Noncoding RNA. 2018 Mar 08;4(1):null
pubmed: 29657304
Mol Cancer. 2018 May 26;17(1):93
pubmed: 29803224
Thorac Cancer. 2018 Aug;9(8):939-949
pubmed: 29897167

Auteurs

Haozhan Yuan (H)

Department of Otolaryngology, The First People's Hospital of Xianyang, Xianyang 712000, People's Republic of China.

Hong Jiang (H)

Department of Otolaryngology, The Nuclear Industry 215 Hospital of Shaanxi Province, Xianyang 712000, People's Republic of China.

Yanting Wang (Y)

Department of Otolaryngology, The First People's Hospital of Xianyang, Xianyang 712000, People's Republic of China.

Yameng Dong (Y)

Department of Otolaryngology, The Nuclear Industry 215 Hospital of Shaanxi Province, Xianyang 712000, People's Republic of China dongym92008@tom.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH